The UK-EU agreement aims to strengthen health security, scientific collaboration and supply-chain resilience, with potential opportunities for pharmaceutical companies.
The European Commission has approved olezarsen for adults with severe hypertriglyceridaemia, following Phase 3 results showing reduced triglyceride levels and fewer acute pancreatitis events.
Laverock Therapeutics appoints new leadership team as it prepares to advance its CAR-T programmes towards clinical development.
A weekly roundup of the latest regulatory updates affecting pharmaceutical development, manufacturing and commercialisation, from new guidance and legislative changes to significant medicine approvals.
Eli Lilly has secured approval for orforglipron in China, becoming the first company to bring an oral GLP-1 receptor agonist for weight management to the country’s market.
Matthew Durdy will step down in June 2027 after nearly 15 years with the organisation, including seven years as CEO, as the Board begins its search for a successor.
The acquisition will expand PharmaLogic’s US radiopharmaceutical manufacturing capacity and establish a transatlantic platform for radioligand therapies.
Three investigational treatments for Huntington’s disease, non-small cell lung cancer and Alzheimer’s disease have received Innovation Passports through the UK’s Innovative Licensing and Access Pathway (ILAP).
A weekly roundup of the latest regulatory developments affecting pharmaceutical research, development and manufacturing, from new guidance and legislative changes to significant medicine approvals.
News plus: The number of patients recruited to industry-sponsored clinical trials in the UK fell by 31 percent between 2022/23 and 2025/26, despite improvements in the speed of trial setup, according to the ABPI.
Merck has signed a definitive agreement to sell its CDMO business to Lonza for a mid-triple-digit million-euro sum, with the transaction expected to complete in mid-2027.
The FDA has issued final guidance outlining a science- and risk-based approach to potency assurance for CGT products, replacing its previous 2011 recommendations and setting out expectations across the product lifecycle.
EnteroBiotix has appointed Dr Murray Stewart, former Chief Medical Officer at GSK, to its Board of Directors as the company advances its Phase 2b programme for irritable bowel syndrome with constipation (IBS-C).
Anthropic has acquired Mithril Medicine, a biotech startup that used its Claude AI models to coordinate an experimental drug development programme for muscular dystrophy.
Six months after the UK’s revised clinical trials regulations came into force, the Medicines and Healthcare products Regulatory Agency (MHRA) has reported an average seven-day approval timeline for eligible substantial trial modifications under its Route B pathway.
News plus. Medicines access, supply chain resilience and manufacturing innovation could reshape the pharmaceutical industry by 2030, but economic pressures and funding models may determine how far these changes translate into benefits for patients.
Vanda Pharmaceuticals has reported positive Phase III results for NEREUS (tradipitant), an NK-1 receptor antagonist, for the prevention of semaglutide-associated vomiting. The company plans to discuss the findings with the FDA ahead of a potential regulatory submission.